Shingles (herpes zoster) recombinant adjuvant virus antigen vaccine
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Vaccine containing recombinant, adjuvanted varicella zoster virus glycoprotein E antigen.
For comprehensive information or advice on this product or the immunisation programme in the UK, the following website should be accessed.
https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book
Drugs List
Therapeutic Indications
Uses
Herpes zoster (shingles): prevention
Herpes zoster related post herpatic neuralgia: prevention
Dosage
Adults
Adults aged 50 years old and older
Initial dose of 0.5ml.
Additional 0.5ml dose to be administered 2 to 6 months after initial dose. Alternatively, in patients who are or may become immunodeficient or immunosuppressed, the second dose may be administered 1 to 2 months after the initial dose.
Adults aged 18 years old and older at an increased risk of herpes zoster
Initial dose of 0.5ml.
Additional 0.5ml dose to be administered 2 to 6 months after initial dose. Alternatively, in patients who are or may become immunodeficient or immunosuppressed, the second dose may be administered 1 to 2 months after the initial dose.
Administration
To be administered by intramuscular injection only, preferably into the deltoid muscle.
Contraindications
Children under 18 years
Febrile disorder
Pregnancy
Precautions and Warnings
History of herpes zoster infection
Immunosuppression
Patients under 50 years
Breastfeeding
Coagulopathy
Immunodeficiency syndromes
Thrombocytopenia
Postpone immunisation if there is active or suspected infection
Advise ability to drive/operate machinery may be affected by side effects
Impaired response possible in immunocompromised patients
Vaccine may not be effective in 100% of patients
Contains polysorbate
Inject other vaccines at different sites
Record name and batch number of administered product
Resuscitation facilities must be immediately available
Risk of Guillain-Barre syndrome may be increased
Follow national immunisation guidelines
Pregnancy and Lactation
Pregnancy
The shingles (herpes zoster) virus antigen vaccine is contraindicated during pregnancy.
The manufacturer recommends as a precautionary measure to avoid the use of shingles (herpes zoster) virus antigen vaccine during pregnancy. At the time of writing, limited published information is available regarding the use of the shingles (herpes zoster) virus antigen vaccine during pregnancy.
Lactation
Use the shingles (herpes zoster) virus antigen vaccine with caution during breastfeeding.
The manufacturer does not make any recommendations regarding the use of the shingles (herpes zoster) virus antigen vaccine during breastfeeding. The effect of the shingles (herpes zoster) virus antigen vaccine on breastfeeding has not been studied. It is unknown if the shingles (herpes zoster) virus antigen vaccine is excreted into breast milk.
Side Effects
Abdominal pain
Angioedema
Arthralgia
Chills
Diarrhoea
Fatigue
Headache
Injection site reactions
Lymphadenopathy
Malaise
Myalgia
Nausea
Pain / soreness (injection site)
Pruritus
Pyrexia
Rash
Swelling (injection site)
Urticaria
Vomiting
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: November 2022
Reference Sources
Summary of Product Characteristics: Shingrix powder and suspension for suspension for injection. GlaxoSmithKline Ltd. Revised June 2022.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 07 November 2022.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.